Horizon To Present Clinical Data On RAYOS Delayed-Release Tablets

(RTTNews) - Horizon Pharma, Inc (HZNP) announced that two published abstracts of its approved treatment RAYOS (prednisone) delayed-release tablets will be presented during the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals Annual Scientific Meeting, October 25-30, 2013 in San Diego, CA.

The abstracts to be presented are: Threshold Analysis of Patient Reported Morning Stiffness Where Delayed-Release Prednisone Was Compared to, and Replaced, Immediate Release Prednisone in Rheumatoid Arthritis (RA) Patients Receiving Conventional Disease-Modifying Antirheumatic Drugs Over 1 Year; and Switching From Immediate Release Prednisone to Delayed Release Prednisone Improves Patient Reported Outcomes In Rheumatoid Arthritis Patients On Conventional Disease-Modifying Antirheumatic Drugs.

In the first analysis, DR prednisone, as compared to IR prednisone, produced significantly higher Morning Stiffness response rates as defined by 25/50/75% improvement thresholds. The time to reach these thresholds is quicker with DR prednisone and patients switched to DR prednisone from IR prednisone quickly "catch up" and manifest comparable responses. Patients treated with DR prednisone maintained their response with no evidence of tachyphylaxis up to 1 year.

The second analysis demonstrated that RA patients on stable DMARD therapy, who have not adequately responded to IR-prednisone with respect to morning stiffness, showed statistically significant and clinically meaningful improvement in this symptom when switched to DR prednisone which markedly impacts quality of life. This beneficial effect was maintained over the 9 month study duration.